Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chemotherapy-Related Cardiac Dysfunction
Marijke Linschoten, Arco J. Teske, Maarten J. Cramer, et al.
Circulation Genomic and Precision Medicine (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 78

Showing 1-25 of 78 citing articles:

Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Effimia Christidi, Liam R. Brunham
Cell Death and Disease (2021) Vol. 12, Iss. 4
Open Access | Times Cited: 461
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 12, pp. 1630-1640
Closed Access | Times Cited: 326
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Matthias Totzeck, Martin Schüler, Martin Stuschke, et al.
International Journal of Cardiology (2019) Vol. 280, pp. 163-175
Closed Access | Times Cited: 185
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies
Georgios Georgiopoulos, Nikolaos Makris, Ageliki Laina, et al.
JACC CardioOncology (2023) Vol. 5, Iss. 1, pp. 1-21
Open Access | Times Cited: 48
Preventing and Treating Anthracycline Cardiotoxicity: New Insights
Konrad Teodor Sawicki, Valentina Sala, Lorenzo Prever, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 309-332
Closed Access | Times Cited: 131
A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid
Hebaallah Mamdouh Hashiesh, Charu Sharma, Sameer N. Goyal, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 140, pp. 111639-111639
Open Access | Times Cited: 56
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children’s Oncology Group
Kelly Getz, Lillian Sung, Bonnie Ky, et al.
Journal of Clinical Oncology (2018) Vol. 37, Iss. 1, pp. 12-21
Open Access | Times Cited: 81
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors
Smita Bhatia
JACC CardioOncology (2020) Vol. 2, Iss. 4, pp. 539-552
Open Access | Times Cited: 66
β-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB2) receptors in rats
Mohamed Fizur Nagoor Meeran, Hasan Al Taee, Sheikh Azimullah, et al.
Chemico-Biological Interactions (2019) Vol. 304, pp. 158-167
Closed Access | Times Cited: 62
Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study
Elisé G. Kaboré, Charles Guénancia, Inês Vaz-Luís, et al.
PLoS Medicine (2019) Vol. 16, Iss. 12, pp. e1002989-e1002989
Open Access | Times Cited: 61
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity
Vivian Y. Chang, Jessica Wang
Current Oncology Reports (2018) Vol. 20, Iss. 7
Open Access | Times Cited: 56
Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes
Effimia Christidi, Haojun Huang, Sanam Shafaattalab, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 43
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma Magavern, Juan Carlos Kaski, Richard M. Turner, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2021) Vol. 8, Iss. 1, pp. 85-99
Open Access | Times Cited: 35
Anthracycline Toxicity: Light at the End of the Tunnel?
Romina B. Cejas, Kateryna Petrykey, Yadav Sapkota, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 115-134
Open Access | Times Cited: 15
Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
Anne Tripaydonis, Rachel Conyers, David A. Elliott
Clinical Pharmacology & Therapeutics (2018) Vol. 105, Iss. 3, pp. 614-624
Open Access | Times Cited: 38
Cardiovascular diseases in survivors of childhood cancer
Neha Bansal, Javier G. Blanco, Umesh C. Sharma, et al.
Cancer and Metastasis Reviews (2020) Vol. 39, Iss. 1, pp. 55-68
Open Access | Times Cited: 38
Heart Failure in Relation to Anthracyclines and Other Chemotherapies
Tolulope A. Agunbiade, Raja Zaghlol, Ana Barac
Methodist DeBakey Cardiovascular Journal (2019) Vol. 15, Iss. 4, pp. 243-243
Open Access | Times Cited: 37
Is there scope for better individualisation of anthracycline cancer chemotherapy?
Benedetta C. Sallustio, Alan V. Boddy
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 2, pp. 295-305
Open Access | Times Cited: 35
Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors
Marie Chaix, Neha Parmar, Caroline Kinnear, et al.
JACC CardioOncology (2020) Vol. 2, Iss. 5, pp. 690-706
Open Access | Times Cited: 34
Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy
Janine A. M. Kamphuis, Marijke Linschoten, Maarten J. Cramer, et al.
Cardio-Oncology (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 33
CELF Family Proteins in Cancer: Highlights on the RNA-Binding Protein/Noncoding RNA Regulatory Axis
Maryam Nasiri Aghdam, Texali-Candelaria Garcia-Garduño, Luis Felipe Jave‐Suárez
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11056-11056
Open Access | Times Cited: 31
Clinical Trial in a Dish
Chi Keung Lam, Joseph C. Wu
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 41, Iss. 3, pp. 1019-1031
Open Access | Times Cited: 30
Cardio oncology: Digital innovations, precision medicine and health equity
Diego Sadler, Tochukwu Okwuosa, Arco J. Teske, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps
Jieli Tong, Isabelle Senechal, Sivatharshini Ramalingam, et al.
British Journal of Hospital Medicine (2025), pp. 1-21
Closed Access
Redefining Survivorship in Pediatric Oncology: A Fresh Look at a Long-Term Problem
Saro H. Armenian, Leontien C. M. Kremer, Emily S. Tonorezos, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
Page 1 - Next Page

Scroll to top